Pancreatic cancer vaccine eradicates deadly disease in more than half of targets in early trials
The pioneering work from Cleveland’s Case Western Reserve University researchers targets pancreatic ductal adenocarcinoma, the most common cancer that plagues the organ. While not the most common form of cancer, pancreatic cancer is particularly insidious, often remaining undetected until it metastasizes. The five-year survival rate is just 13.3%. In preclinical trials, the vaccine eliminated the cancer in more than half of the targets.
